Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Endowments recover returns in 2013 - NACUBO-Commonfund Study of Endowments

Wednesday, January 29, 2014

Bailey McCann, Opalesque New York:

The annual NACUBO-Commonfund Study of Endowments, shows that FY2013 was a strong recovery year for endowment portfolios, coming off the -0.3% return reported for FY2012. Total returns were 11.7% net of fees - a closely watched number as endowments not only fund school budgets but also reflect the overall results of significant allocations to hedge funds and alternative investments.

This is the fifth year for the study, which acts as a league table of sorts for the nations top schools. The study represents 835 US institutional participants and total endowment market assets of $448.6bn. The average endowment of U.S. institutions was $539.8m, and the median $97.6m.

The key take away for hedge funds is that the rebound this year shows that overall, the endowment model of allocations to hedge funds still works. Report data shows that over ten years, endowments of all size categories produced much higher returns than the 60/40 S&P/Barclays Blend allocation (60% Stocks, 40% Bonds). Since 2003, report data shows that save for a few flat/down years ('08, '09, 12) the 11.7% return of this year reflects a return to more typical performance. Overall, the asset allocation (see below) mix remains mostly the same although there has been some movement away from fixed income and alternatives, which may reflect some defensive positioning as a result of the start of taper.

......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for